Sistema de Salut de Catalunya
Institut Català de la Salut
[Navarro-Díaz M] Genomic Platform, Germans Trias i Pujol’s Research Insitute, Badalona, Spain. Nephrology Department, Sant Joan Despí Moisès Broggi Hospital, Sant Joan Despí, Spain. [López-Martínez M] Servei de Nefrologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain
Vall d'Hebron Barcelona Hospital Campus
2025-08-18T08:26:08Z
2025-08-18T08:26:08Z
2025-05
Biomarker; MicroRNA; Obesity-related glomerulopathy
Biomarcador; MicroARN; Glomerulopatia relacionada amb l'obesitat
Biomarcador; MicroARN; Glomerulopatía relacionada con la obesidad
Obesity increases the risk of cardiovascular disease, diabetes and chronic kidney disease. Obesity-related glomerulopathy (ORG) is a potentially reversible cause of kidney disease that often progresses silently until it reaches irreversible stages. However, we are still lacking a sensitive and specific biomarker to identify patients with obesity who are at risk of developing CKD. The role of microRNAs (miRNAs) has emerged as a promising area for diagnostic and therapeutic applications in kidney disease. Recent research has highlighted the specific roles of various miRNAs in renal function, showing that their dysregulation can contribute to the development of kidney diseases. This review will discuss the emerging role of miRNAs in the context of ORG, focusing on their potential as biomarkers and therapeutic targets for this increasingly prevalent disease.
Article
Versió publicada
Anglès
Ronyons - Malalties - Tractament; Ronyons - Malalties - Diagnòstic; Obesitat; Marcadors bioquímics; MicroARN; DISEASES::Nutritional and Metabolic Diseases::Nutrition Disorders::Overnutrition::Obesity; CHEMICALS AND DRUGS::Biological Factors::Biomarkers; CHEMICALS AND DRUGS::Nucleic Acids, Nucleotides, and Nucleosides::Antisense Elements (Genetics)::RNA, Antisense::MicroRNAs; DISEASES::Male Urogenital Diseases::Urologic Diseases::Kidney Diseases; Other subheadings::Other subheadings::/diagnosis; HEALTH CARE::Health Services Administration::Patient Care Management::Disease Management; ENFERMEDADES::enfermedades nutricionales y metabólicas::trastornos nutricionales::hipernutrición::obesidad; COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadores; COMPUESTOS QUÍMICOS Y DROGAS::nucleótidos y nucleósidos de ácidos nucleicos::elementos antisentido (genética)::ARN antiparalelo::microARN; ENFERMEDADES::enfermedades urogenitales masculinas::enfermedades urológicas::enfermedades renales; Otros calificadores::Otros calificadores::/diagnóstico; ATENCIÓN DE SALUD::administración de los servicios de salud::gestión de la atención al paciente::tratamiento de las enfermedades
MDPI
Biomedicines;13(5)
https://doi.org/10.3390/biomedicines13051030
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - HVH [3440]
